7 articles
The United States and the United Kingdom have finalized a deal to lower prescription drug prices. The agreement aims to make other countries contribute more to the costly research and development of new medicines, potentially reducing costs for American patients and insurers. This development comes as tensions rise over the Strait of Hormuz, impacting global energy markets.
Novo Nordisk's new oral weight loss pill, Wegovy, has seen a strong launch with over 500,000 prescriptions written in its first month. The drug aims to overcome patient reluctance towards injections, though side effects like nausea are present. The company faces stiff competition from Eli Lilly, which recently launched its own rival pill with fewer restrictions.
The FDA has significantly reduced drug approval times, cutting average reviews by up to two months. This efficiency drive, aided by AI, aims to bring life-saving treatments to patients faster without compromising safety. Pharmaceutical companies are set to benefit from quicker market access and potentially lower R&D costs.
President Trump escalates military action in Iran, destroying a major bridge and threatening further strikes. Simultaneously, new 100% tariffs on imported drugs aim to lower prices and boost U.S. production, while Attorney General Pam Bondi departs.
The U.S. government is now potentially classifying microplastics and pharmaceuticals as drinking water contaminants, validating long-held public concerns. This marks a significant shift towards studying and understanding the health impacts of these widespread substances.
The FDA is dramatically speeding up drug reviews with a new priority program, leading to approvals in record time, sometimes within 60 days. This initiative aims to bring life-changing therapies to patients faster by cutting red tape and streamlining processes, without compromising safety. The agency is also tackling issues like illegal marketing of compounded drugs and improving drug safety reporting.
Advancements in cystic fibrosis treatment have more than doubled life expectancy, forcing a significant reevaluation of financial planning, retirement goals, and long-term career viability for affected individuals. The shift from survival to sustained living introduces new uncertainties and market opportunities.
